home All News open_in_new Full Article

Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016

AMSTERDAM, ZUG, Switzerland & GDAŃSK, Poland — Polpharma Biologics S.A. (“Polpharma Biologics”) announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosimilar to vedolizumab, an integrin receptor antagonist, (reference product: Entyvio®*), a biologic therapy indicated for moderate to severe ulcerative colitis and […]


today 1 week ago attach_file Other

attach_file Other
attach_file Other
attach_file Other
attach_file Events
attach_file Other
attach_file Other
attach_file Politics
attach_file Sport
attach_file Other
attach_file Other
attach_file Economics
attach_file Other
attach_file Economics
attach_file Events
attach_file Economics
attach_file Other
attach_file Politics
attach_file Other
attach_file Other
attach_file Economics


ID: 4120860326
Add Watch Country

arrow_drop_down